CTOs on the Move

Fruit Street

www.fruitstreet.com

 
Fruit Street delivers the CDC`s Diabetes Prevention Program using telehealth, wearable devices, and mobile applications. The diabetes prevention program is a 1-year long diet and lifestyle intervention designed to help pre-diabetic patients lose 5-7% of their weight through diet and lifestyle changes. The program is based on clinical research that was published in the New England Journal of Medicine in 2002 which showed that patients who complete the program have a 58% risk reduction for developing diabetes.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Ian McFarland
Chief Technology Officer Profile

Similar Companies

LaBEX of MA

LaBEX of MA is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North Coast Clinical Laboratory

North Coast Clinical Laboratory is a Sandusky, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Active Ice Inc

Active Ice Inc is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.

MediConnect Global

MediConnect Global is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.